International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 4 , Pages 1003-1010 , 15 March 2005

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Presented at the 86th Annual Meeting of the American Radium Society, Napa, CA, May 1–5, 2004.

  • Steven J. Feigenberg, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Steven J. Feigenberg, M.D., Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111-2497. Tel: (215) 728-3022; Fax: (215) 214-1629
    • ,
  • Alexandra L. Hanlon, Ph.D.

      Affiliations

    • Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Eric M. Horwitz, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Robert G. Uzzo, M.D.

      Affiliations

    • Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Debra F. Eisenberg, M.S.

      Affiliations

    • Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Alan Pollack, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA

Received 4 June 2004 ,Revised 22 July 2004 ,Accepted 23 July 2004.

References 

  1. Bolla M , Gonzalez D , Warde P , et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin . N Engl J Med . 1997;337:295–300
  2. Bolla M , Collette L , Blank L , et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial . Lancet . 2002;360:103–106
  3. Pilepich MV , Caplan R , Byhardt RW , et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31 . J Clin Oncol . 1997;15:1013–1021
  4. Hanks GE , Pajak TF , Porter A , et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 . J Clin Oncol . 2003;21:3972–3978
  5. Pilepich MV , Winter K , John MJ , et al.  Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate . Int J Radiat Oncol Biol Phys . 2001;50:1243–1252
  6. Roach M , Lu J , Pilepich MV , et al.  Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys . 2000;47:617–627
  7. Chism DB , Hanlon AL , Horwitz EM , et al.  A comparison of the single vs. double high-risk factor stratification systems for prostate cancer treated radiotherapy without androgen deprivation . Int J Radiat Oncol Biol Phys . 2003;57:S270
  8. D'Amico AV , Whittington R , Malkowicz SB , et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer . JAMA . 1998;280:969–974
  9. D'Amico AV , Desjardin A , Chung A , et al.  Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy . Semin Urol Oncol . 1998;16:153–159
  10. D'Amico AV , Whittington R , Malkowicz SB , et al.  Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer . Urology . 2000;55:572–577
  11. D'Amico AV , Cote K , Loffredo M , et al.  Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era . J Urol . 2003;170:S42–S47
  12. D'Amico AV , Cote K , Loffredo M , et al.  Pretreatment predictors of time to cancer specific death after prostate specific antigen failure . J Urol . 2003;169:1320–1324
  13. Partin AW , Yoo J , Carter HB , et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer . J Urol . 1993;150:110–114
  14. Partin AW , Kattan MW , Subong EN , et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update . JAMA . 1997;277:1445–1451
  15. Zagars GK , Pollack A . Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome . Urology . 1995;45:476–483
  16. Zelefsky MJ , Harrison A . Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy . Urology . 1997;49:38–45
  17. Zelefsky MJ , Leibel SA , Gaudin PB , et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer . Int J Radiat Oncol Biol Phys . 1998;41:491–500
  18. Pollack A , Zagars GK , Starkschall G , et al.  Prostate cancer radiation dose response: Results of the M (D. Anderson phase III randomized trial) . Int J Radiat Oncol Biol Phys . 2002;53:1097–1105
  19. Roach M , Weinberg V , McLaughlin PW , et al.  Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate . Urology . 2003;61:730–735
  20. Shipley WU , Thames HD , Sandler HM , et al.  Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis . JAMA . 1999;281:1598–1604
  21. Sanguineti G , Agostinelli S , Foppiano F , et al.  Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma . Br J Cancer . 2002;86:1843–1847
  22. Feigenberg SJ , Hanlon AL , Horwitz EM , et al.  Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy . Int J Radiat Oncol Biol Phys . 2003;57:S176
  23. Hanks GE , Hanlon AL , Epstein B , et al.  Dose response in prostate cancer with 8–12 years' follow-up . Int J Radiat Oncol Biol Phys . 2002;54:427–435
  24. International Commission on Radiation Units and Measurements . ICRU report 50: Prescribing, recording, and reporting photon beam therapy . Bethesda: ICRU; 1993;
  25. Cox JD , Gallagher MJ , Hammond EH  for the American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy . J Clin Oncol . 1999;17:1555
  26. Ciampi ATJ , Nakache J-P , Asselain B . Stratification by stepwise regression, correspondence analysis and recursive partition . Comput Stat Data Analysis . 1986;4:185–204
  27. Segal MR . Regression trees for censored data . Biometrics . 1988;44:35–47
  28. Zhang HP, Singer B. Recursive partitioning in the health sciences. New York: Springer-Verlag; 1999.
  29. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457–481
  30. Wilcoxon F. Individual comparison by ranking methods. Biometrics 1945;1:80–83.
  31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
  32. Lehmann EL. Nonparametrics: Statistical methods based on ranks. San Francisco: Holden-Day; 1975.
  33. Pilepich M . Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate: Long-term results of phase III RTOG study 85–31 . Int J Radiat Oncol Biol Phys . 2003;57:S172–S173
  34. Horwitz EM , Hanlon AL , Pinover WH , et al.  Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques . Cancer . 2001;92:1281–1287
  35. Zietman AL , Shipley WU , Coen JJ . Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen followup . J Urol . 1994;152:1806–1812
  36. Zietman AL , Coen JJ , Shipley WU , et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome . J Urol . 1994;151:640–645
  37. Hanks GE , Lee WR , Schultheiss TE . Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation . J Urol . 1995;154:456–459
  38. Lee WR , Hanks GE , Schultheiss TE , et al.  Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen–driven outcome analysis . J Clin Oncol . 1995;13:464–469
  39. Pisansky TM , Cha SS , Earle JD , et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer . J Clin Oncol . 1993;11:2158–2166
  40. Pisansky TM , Kahn MJ , Rasp GM , et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma . Cancer . 1997;79:337–344
  41. D'Amico AV , Whittington R , Malkowicz SB , et al.  Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial . J Clin Oncol . 1997;15:1465–1469
  42. D'Amico AV , Whittington R , Schultz D , et al.  Outcome based staging for clinically localized adenocarcinoma of the prostate . J Urol . 1997;158:1422–1426
  43. Ragde H , Blasko JC , Grimm PD , et al.  Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma . Cancer . 1997;80:442–453
  44. Blasko JC , Wallner K , Grimm PD , et al.  Prostate specific antigen based disease control following ultrasound guided–iodine implantation for stage T1/T2 prostatic carcinoma . J Urol . 1995;154:1096–1099
  45. Lerner SE , Blute ML , Zincke H . Risk factors for progression in patients with prostate cancer treated with radical prostatectomy . Semin Urol Oncol . 1996;14:12–21
  46. Zagars GK , Pollack A , Kavadi VS , et al.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer . Int J Radiat Oncol Biol Phys . 1995;32:293–306
  47. Partin AW , Piantadosi S , Sanda MG , et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy . Urology . 1995;45:831–838
  48. Wallner K , Roy J , Harrison L . Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma . J Clin Oncol . 1996;14:449–453
  49. Pollack A , Smith LG , von Eschenbach AC . External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era . Int J Radiat Oncol Biol Phys . 2000;48:507–512
  50. Pollack A , Hanlon AL , Horwitz EM , et al.  Prostate cancer radiotherapy dose response: An update of the Fox Chase experience . J Urol . 2004;171:1132–1136
  51. Zelefsky M , Fuks Z , Chan H , et al.  Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer . Int J Radiat Oncol Biol Phys . 2003;57:S149–S150

PII: S0360-3016(04)02131-5

doi: 10.1016/j.ijrobp.2004.07.725

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 4 , Pages 1003-1010 , 15 March 2005

Article Tools

* Image Usage & Resolution